Effectiveness of Different P2Y12 Inhibitors on Coronary Flow in Patients with ST-Elevation Myocardial Infarction

1. Townsend N, Wilson L, Bhatnagar P, Wickramasinghe K, Rayner M, Nichols M. Cardiovascular disease in Europe: epidemiological update 2016. Eur Heart J. 2016;37:3232-3245. doi: 10.1093/eurheartj/ehw334.10.1093/eurheartj/ehw334Search in Google Scholar

2. Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39:119-177. doi: 10.1093/eurheartj/ehx393.10.1093/eurheartj/ehx393Search in Google Scholar

3. Hartley A, Marshall DC, Salciccioli JD, Sikkel MB, Maruthappu M, Shalhoub J. Trends in Mortality From Ischemic Heart Disease and Cerebrovascular Disease in Europe: 1980 to 2009. Circulation. 2016;133:1916-1926. doi: 10.1161/circulationaha.115.018931.10.1161/CIRCULATIONAHA.115.018931Search in Google Scholar

4. Puymirat E, Simon T, Steg PG, et al. Association of changes in clinical characteristics and management with improvement in survival among patients with ST-elevation myocardial infarction. JAMA. 2012;308:998-1006. doi: 10.1001/2012. jama.11348.10.1001/2012.jama.11348Search in Google Scholar

5. Resnic FS, Wainstein M, Lee MK, et al. No-reflow is an independent predictor of death and myocardial infarction after percutaneous coronary intervention. Am Heart J. 2003;145:42-46. doi: 10.1067/mhj.2003.36.10.1067/mhj.2003.36Search in Google Scholar

6. Hamada S, Nishiue T, Nakamura S, et al. TIMI frame count immediately after primary coronary angioplasty as a predictor of functional recovery in patients with TIMI 3 reperfused acute myocardial infarction. J Am Coll Cardiol. 2001;38:666-671. doi: 10.1016/s0735-1097(01)01424-3.10.1016/S0735-1097(01)01424-3Search in Google Scholar

7. Gibson CM, Cannon CP, Daley WL, et al. TIMI frame count: a quantitative method of assessing coronary artery flow. Circulation. 1996;93:879-888 doi: 10.1161/01.cir.93.5.879.10.1161/01.CIR.93.5.879Search in Google Scholar

8. Angeja BG, Gunda M, Murphy SA, et al. TIMI myocardial perfusion grade and ST segment resolution: association with infarct size as assessed by single photon emission computed tomography imaging. Circulation. 2002;105:282-285. doi: 10.1161/hc0302.103588.10.1161/hc0302.10358811804979Search in Google Scholar

9. Thygesen K, Alpert JS, Jaffe AS, et al. Fourth Universal Definition of Myocardial Infarction (2018). Circulation. 2018;138:e618-e651. doi: 10.1161/cir.0000000000000617.10.1161/CIR.000000000000061730571511Search in Google Scholar

10. van ‘t Hof AW, Liem A, Suryapranata H, Hoorntje JC, de Boer MJ, Zijlstra F. Angiographic assessment of myocardial reperfusion in patients treated with primary angioplasty for acute myocardial infarction: myocardial blush grade. Zwolle Myocardial Infarction Study Group. Circulation. 1998;97:2302-2306. doi: 10.1161/01.cir.97.23.2302.10.1161/01.CIR.97.23.2302Search in Google Scholar

11. Fabris E, van ‘t Hof A, Hamm CW, et al. Clinical impact and predictors of complete ST segment resolution after primary percutaneous coronary intervention: A subanalysis of the ATLANTIC Trial. Eur Heart J Acute Cardiovasc Care. 2019;8:208-217. doi: 10.1177/2048872617727722.10.1177/204887261772772228841028Search in Google Scholar

12. Gibson CM, Cannon CP, Murphy SA, Marble SJ, Barron HV, Braunwald E. Relationship of the TIMI myocardial perfusion grades, flow grades, frame count, and percutaneous coronary intervention to long-term outcomes after thrombolytic administration in acute myocardial infarction. Circulation. 2002;105:1909-1913. doi: 10.1161/01.cir.0000014683.52177.b5.10.1161/01.CIR.0000014683.52177.B5Search in Google Scholar

13. Winter JL, Lindefjeld DS, Veas N, et al. Angiographic and electrocardiographic parameters of myocardial reperfusion in angioplasty of patients with ST elevation acute myocardial infarction loaded with ticagrelor or clopidogrel (MICAMITICLO trial). Cardiovasc Revasc Med. 2014;15:284-288. doi: 10.1016/j.carrev.2014.07.001.10.1016/j.carrev.2014.07.001Search in Google Scholar

14. Hoffmann R, Haager P, Arning J, et al. Usefulness of myocardial blush grade early and late after primary coronary angioplasty for acute myocardial infarction in predicting left ventricular function. Am J Cardiol. 2003;92:1015-1019. doi: 10.1016/j. amjcard.2003.07.001.10.1016/j.amjcard.2003.07.001Search in Google Scholar

15. Haager PK, Christott P, Heussen N, Lepper W, Hanrath P, Hoffmann R. Prediction of clinical outcome after mechanical revascularization in acute myocardial infarction by markers of myocardial reperfusion. J Am Coll Cardiol. 2003;41:532-538. doi: 10.1016/s0735-1097(02)02870-x.10.1016/S0735-1097(02)02870-XSearch in Google Scholar

16. Kaya MG, Arslan F, Abaci A, van der Heijden G, Timurkaynak T, Cengel A. Myocardial blush grade: a predictor for major adverse cardiac events after primary PTCA with stent implantation for acute myocardial infarction. Acta Cardiol. 2007;62:445-451. doi: 10.2143/ac.62.5.2023406.10.2143/AC.62.5.202340617982964Search in Google Scholar

17. Brener SJ, Dizon JM, Mehran R, et al. Complementary prognostic utility of myocardial blush grade and ST-segment resolution after primary percutaneous coronary intervention: analysis from the HORIZONS-AMI trial. Am Heart J. 2013;166:676-683. doi: 10.1016/j.ahj.2013.07.025.10.1016/j.ahj.2013.07.02524093847Search in Google Scholar

18. Di Vito L, Versaci F, Limbruno U, et al. Impact of oral P2Y12 inhibitors on residual thrombus burden and reperfusion indexes in patients with ST-segment elevation myocardial infarction. J Cardiovasc Med (Hagerstown). 2016;17:701-706. doi: 10.2459/jcm.0000000000000392.10.2459/JCM.000000000000039227467458Search in Google Scholar

19. Savi P, Zachayus JL, Delesque-Touchard N, et al. The active metabolite of Clopidogrel disrupts P2Y12 receptor oligomers and partitions them out of lipid rafts. Proc Natl Acad Sci U S A. 2006;103:11069-11074. doi: 10.1073/pnas.0510446103.10.1073/pnas.0510446103163515316835302Search in Google Scholar

20. Algaier I, Jakubowski JA, Asai F, von Kugelgen I. Interaction of the active metabolite of prasugrel, R-138727, with cysteine 97 and cysteine 175 of the human P2Y12 receptor. J Thromb Haemost. 2008;6:1908-1914. doi: 10.1111/j.1538-7836.2008.03136.x.10.1111/j.1538-7836.2008.03136.x18752581Search in Google Scholar

21. Cattaneo M. New P2Y(12) inhibitors. Circulation. 2010;121:171-179. doi: 10.1161/circulationaha.109.853069.10.1161/CIRCULATIONAHA.109.85306920048234Search in Google Scholar

22. Vang JJ, Nilsson L, Berntsson P, et al. Ticagrelor binds to human P2Y(12) independently from ADP but antagonizes ADP-induced receptor signaling and platelet aggregation. J Thromb Haemost. 2009;7:1556-1165. doi: 10.1111/j.1538-7836.2009.03527.x.10.1111/j.1538-7836.2009.03527.x19552634Search in Google Scholar

23. Jeon HS, Kim MJ, Choi HY, et al. Pharmacokinetics and pharmacodynamics of ticagrelor and prasugrel in healthy male Korean volunteers. Clin Ther. 2015;37:563-573. doi: 10.1016/j.clinthera.2015.01.010.10.1016/j.clinthera.2015.01.01025697420Search in Google Scholar

24. Hagihara K, Kazui M, Kurihara A, et al. A possible mechanism for the differences in efficiency and variability of active metabolite formation from thienopyridine antiplatelet agents, prasugrel and clopidogrel. Drug Metab Dispos. 2009;37:2145-2152. doi: 10.1124/dmd.109.028498.10.1124/dmd.109.02849819704027Search in Google Scholar

25. Parodi G, Valenti R, Bellandi B, et al. Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study. J Am Coll Cardiol. 2013;61:1601-1606. doi: 10.1016/j.jacc.2013.01.024.10.1016/j.jacc.2013.01.02423500251Search in Google Scholar